Research programme: parathyroid hormone analogues - Chugai

Drug Profile

Research programme: parathyroid hormone analogues - Chugai

Alternative Names: SP-PTH

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Peptide hormones
  • Mechanism of Action Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypoparathyroidism

Most Recent Events

  • 16 Sep 2016 Pharmacodynamics data from a preclinical trial presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypoparathyroidism in Japan (SC, Injection)
  • 07 Oct 2008 Preclinical trials in Hypoparathyroidism in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top